Quick Answer
Karyopharm Therapeutics Inc. reported Total Assets of $108.42 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -34.1% in Total Assets from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $149.29 million | Q2 2014: $137.68 million | Q3 2014: $235.16 million | Q1 2015: $292.04 million | Q2 2015: $263.29 million | Q3 2015: $236.97 million | Q1 2016: $192.14 million | Q2 2016: $170.90 million | Q3 2016: $183.62 million | Q1 2017: $155.44 million | Q2 2017: $185.75 million | Q3 2017: $163.77 million | Q1 2018: $146.37 million | Q2 2018: $256.59 million | Q3 2018: $219.99 million | Q1 2019: $287.21 million | Q2 2019: $238.10 million | Q3 2019: $297.75 million | Q1 2020: $416.14 million | Q2 2020: $380.01 million | Q3 2020: $337.59 million | Q1 2021: $274.91 million | Q2 2021: $286.57 million | Q3 2021: $254.09 million | Q1 2022: $294.03 million | Q2 2022: $256.48 million | Q3 2022: $231.24 million | Q1 2023: $325.80 million | Q2 2023: $297.83 million | Q3 2023: $269.96 million | Q1 2024: $204.46 million | Q2 2024: $213.98 million | Q3 2024: $189.48 million | Q1 2025: $127.71 million | Q2 2025: $104.88 million | Q3 2025: $96.23 million.
- Over the full 14 years of available data (2012 to 2025), Karyopharm Therapeutics Inc.'s Total Assets has grown by 8,169.7%.
- Historical annual values: Fiscal year 2025: $108.42 million | Fiscal year 2024: $164.42 million | Fiscal year 2023: $240.44 million | Fiscal year 2022: $358.17 million | Fiscal year 2021: $305.31 million | Fiscal year 2020: $313.05 million | Fiscal year 2019: $294.96 million | Fiscal year 2018: $341.19 million | Fiscal year 2017: $180.29 million | Fiscal year 2016: $180.39 million | Fiscal year 2015: $215.44 million | Fiscal year 2014: $220.34 million | Fiscal year 2013: $158.23 million | Fiscal year 2012: $1.31 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: